Apomorphine and Schizophrenia: Treatment, CSF, and Neuroendocrine Responses

Michael I. Levy, Bonnie M. Davis, Richard C. Mohs, Kenneth S. Kendler, Alexander A. Mathe, Gaston Trigos, Thomas B. Horvath, Kenneth L. Davis

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Previous studies have variably reported the efficacy of apomorphine in treatment of schizophrenia and tardive dyskinesia. Stimulation of dopamine neuron autoreceptors is the presumed mode of action. Low-dose apomorphine (0.75 mg subcutaneously) and placebo were administered to 25 male schizophrenics to evaluate the drug's effect on psychotic and tardive dyskinetic symptoms. No significant improvement or deterioration was seen. Concomitant measurements of plasma prolactin and growth hormone levels and CSF homovanillic acid level indicated that the dose used was centrally active. These results indicate that an active though nonsedating dose of apomorphine does not ameliorate symptoms of schizophrenia or tardive dyskinesia.

Original languageEnglish
Pages (from-to)520-524
Number of pages5
JournalArchives of General Psychiatry
Volume41
Issue number5
DOIs
StatePublished - May 1984
Externally publishedYes

Fingerprint

Dive into the research topics of 'Apomorphine and Schizophrenia: Treatment, CSF, and Neuroendocrine Responses'. Together they form a unique fingerprint.

Cite this